Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs reduce diabetic nephropathy
Renal · ACEARB-RENAL-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across several large, well-run trials, blocking the renin-angiotensin system lowered the amount of protein leaking into the urine and slowed kidney decline in people with diabetes. In type 2 diabetes the strongest trials used angiotensin-receptor blockers and showed fewer patients reaching hard kidney outcomes such as a doubling of the blood creatinine level or kidney failure [1][2], and one trial showed the drug delayed the move from mild to overt kidney disease [3]. An older ACE-inhibitor trial showed stable kidney function and urine protein over five years, but it was small and measured a kidney marker rather than kidney failure itself [8]. The panel treated the claim as well supported because the benefit reaches real kidney endpoints and is reported as independent of blood-pressure lowering, not only the urine marker. It held back from the very top because the type 2 ACE-inhibitor evidence here is thinner than the ARB evidence, combining the two drug classes did not add benefit and raised harms [17], and no benefit was shown in very advanced kidney disease [11].
Urine albumin falls consistently with both drug classes: losartan cut proteinuria by 35% [1] and albuminuria by 28% [5], candesartan and lisinopril reduced the urinary albumin:creatinine ratio by 30% and 46% respectively [4], and losartan and enalapril reduced albuminuria by 33% to 59% in type 1 diabetes [19]. Progression on hard endpoints is shown in the two largest type 2 nephropathy trials: losartan lowered the risk of doubling serum creatinine by 25% and end-stage renal disease by 28% [1], and irbesartan lowered the primary composite endpoint by 20% versus placebo [2]. Irbesartan also reduced progression to overt nephropathy, with a hazard ratio of 0.30 at 300 mg [3]. The ACE-inhibitor limb rests mainly on a five-year trial of 94 normotensive patients showing stabilised creatinine and albuminuria [8], supported by a 22-patient study [22]. Several trials report the effect as independent of blood-pressure reduction [1][2][3][8]. The contested point: The evidence divides on whether the ACE-inhibitor half of the claim is carried on hard renal outcomes in type 2 diabetes, where it rests largely on the surrogate-focused N=94 trial [8] and the small [22], while the ARB half reaches doubling of creatinine and end-stage renal disease [1][2]. It also divides by scope: the drugs are not beneficial as combination therapy [17] and showed no continuation benefit in advanced chronic kidney disease [11].
All 35 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The phrase 'ACEi and ARBs' must not be read as combination therapy: VA NEPHRON-D [17] found ACEi+ARB gave no renal benefit (HR 0.88, 95% CI 0.70 to 1.12) and increased hyperkalemia and acute kidney injury, stopping early for safety.
Hard-endpoint evidence (doubling of creatinine, ESRD) in T2D is ARB-dominated [1][2][3]; the T2D ACEi evidence here rests largely on a surrogate-focused N=94 trial [8] and a small N=22 study [22], so the ACEi limb for hard progression is thinner than the claim implies.
Where it remains uncertain. The type 2 ACE-inhibitor hard-outcome evidence is thin, resting on a surrogate-focused N=94 trial [8], and benefit does not extend to combination therapy [17] or advanced CKD [11].
Aleatory
The ACEi evidence leans on trials of 94 [8] and 22 [22] patients, and a 20-patient crossover [10], where play of chance around the effect is large.
Epistemic
No trial in this corpus shows an ACE inhibitor reducing doubling of creatinine or end-stage renal disease in type 2 diabetes; [8] measured a surrogate and creatinine stability only.
Inferential
The claim that lowering albuminuria slows progression relies on the albuminuria-to-outcome relationship, which [5] and [14] establish through post-hoc and associational analysis carrying residual-confounding risk.
The load-bearing papers from a corpus of 35, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Landmark ARB RCT: slows progression on hard renal endpoints, BP-independent.
“The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).”
Panel auditInternal validity: high · scope of inference: Type 2 diabetic patients with established nephropathy (overt proteinuria).Key limitations: no effect on death · background antihypertensives varied
Independent ARB RCT confirming slowed progression, BP-independent.
“Treatment with irbesartan was associated with a risk of the primary composite end point that was 20 percent lower than that in the placebo group (P=0.02)”
Panel auditInternal validity: high · scope of inference: Hypertensive type 2 diabetic patients with overt nephropathy.Key limitations: ESRD reduction not individually significant (P=0.07) · 2.6-year follow-up
ARB slows progression from microalbuminuria to overt nephropathy.
“Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p < 0.001”
Panel auditInternal validity: high · scope of inference: Hypertensive type 2 diabetic patients with microalbuminuria.Key limitations: 150 mg arm not significant (p=0.08) · surrogate progression endpoint
GFR decline and secondary endpoints did not differ significantly between the ARB and the ACEi (non-inferiority met).
Panel auditInternal validity: medium · scope of inference: Type 2 diabetic patients with early nephropathy.Key limitations: no placebo arm · early nephropathy only · small sample
4 of 35 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Landmark, consistent RCT evidence carries both limbs of the claim, held just below the top of the band because the T2D hard-outcome evidence is ARB-weighted, combination therapy does not share the benefit [17], and benefit is not demonstrated in advanced CKD [11].
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
ACE-inhibitor hard-endpoint trial in type 2 diabetic nephropathy. The ACEi limb of the claim for hard progression is carried only by surrogate and small studies [8][22], unlike the ARB limb [1][2]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled RCT of an ACE inhibitor in type 2 diabetic nephropathy powered on doubling of creatinine and end-stage renal disease.
Open question: Do ACE inhibitors reduce hard renal endpoints in type 2 diabetic nephropathy, as ARBs do? Why it is still open: The corpus shows ARB hard-endpoint benefit [1][2] but only ACEi surrogate stabilisation in a 94-patient trial [8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19